Benjamin M. Weide

Benjamin M. Weide

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: December 04, 2025

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Journal: Nature communications

Published: July 24, 2025

Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab.

Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab.

Journal: Oncology

Published: June 01, 2023

Putative Cancer Stem Cell Markers are Frequently Expressed by Melanoma Cells in Vitro and in Situ but are also Present in Benign Differentiated Cells.

Putative Cancer Stem Cell Markers are Frequently Expressed by Melanoma Cells in Vitro and in Situ but are also Present in Benign Differentiated Cells.

Journal: Frontiers in bioscience (Landmark edition)

Published: May 17, 2023

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: April 28, 2023

Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.

Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.

Journal: Frontiers in immunology

Published: March 28, 2022

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.

Journal: Journal for immunotherapy of cancer

Published: November 01, 2021

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 23, 2021

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.

Journal: Nature communications

Published: May 14, 2021

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

Journal: Journal for immunotherapy of cancer

Published: April 13, 2021

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.

Journal: Targeted oncology

Published: January 16, 2021

Showing 1-12 of 104

Last Updated: 09/26/2026